| Date | Title | Description |
| 02.05.2025 | The New Wave of Acquisitions: Navigating Tariff Turbulence and Gaming Growth | In the ever-shifting landscape of global business, two companies stand out: Recordati and Dream Games. Both are poised for growth, but their paths diverge. Recordati, an Italian pharmaceutical firm, eyes acquisitions amid tariff volatility.... |
| 30.04.2025 | Italy’s Recordati Sees Tariff Volatility Fueling Dealmaking | (Bloomberg) -- Italian drugmaker Recordati SpA is on the lookout for acquisitions, saying market volatility and the impact of tariffs have created the potential for cheaper buyouts.
Recordati, which is backed by private equity firm CVC Capi... |
| 18.03.2022 | Recordati Completes the Acquisition of EUSA Pharma | Mar 18 2022
MILAN, Italy—Following the positive outcome of the regulatory clearances process, Recordati announces today the closing of the previously announced acquisition of EUSA Pharma (UK) Ltd(1), a global specialty pharmaceutical compa... |
| 02.04.2020 | UK tech companies tackling Covid-19 – from detection to vaccination | The 2020 Tech Nation Report revealed that UK healthtech investment has doubled since 2017, reaching £1.7bn in 2019. And this world-leading sector has just become more crucial than ever. Faced with a global pandemic, innovative scaling compa... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 19.03.2020 | FDA unveils guidance for Covid-19 trials | The FDA on Wednesday issued new final guidance to help sponsors assure the safety of trial participants, maintain compliance with good clinical practice (GCP) and minimize the risks to trial integrity during the Covid... |
| 22.08.2019 | EW Healthcare Partners Raises Over $745 Million Fund 2 | Aug 22 2019
Team of Experienced Healthcare Investors and Former Healthcare Executives Will Invest in Select Healthcare Companies to Seek to Accelerate Their Revenue Growth
Partner and Principals Promoted in London, New York and Palo Alto ... |
| 18.07.2018 | EUSA PHARMA ANNOUNCES ACQUISITION OF GLOBAL RIGHTS TO SYLVANT® (SILTUXIMAB) FROM JANSSEN SCIENCES IRELAND UC FOR $115 MILLION | - |
| 18.07.2018 | EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million | Jul 18 2018
HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare diseases, announced today that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary ... |
| 07.03.2018 | EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors | Mar 07 2018
HEMEL HEMPSTEAD, England –– EUSA Pharma (EUSA), a world-class specialty pharmaceutical company focused on oncology and oncology supportive care, today announced the appointment of Rolf K Hoffmann to its Board of Directors. Mr H... |
| 15.11.2017 | EUSA Pharma and AVEO Oncology Announce First Commercial Launch of FOTIVDA (tivozanib) | Nov 15 2017
HEMEL HEMPSTEAD, England & CAMBRIDGE, Massachusetts. – – EUSA Pharma and AVEO Oncology (NASDAQ: AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In t... |
| 18.10.2017 | EW Healthcare Partners Announces the Appointment of Three Senior Executives | Oct 18 2017
NEW YORK, New York—EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the addition of three senior executives to their investment team:
• Lamberto Andreotti,... |
| 23.06.2017 | EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment | Jun 23 2017
HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency’s Committee for Medicinal Products fo... |
| 09.05.2017 | European Commission Approves the Only Immunotherapy for High-Risk Neuroblastoma | May 09 2017
HEMEL HEMPSTEAD, England – EUSA Pharma today announced that the European Commission (EC) has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk neuroblastoma in patients aged 12 months and above... |
| 27.03.2017 | EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for Dinutuximab Beta | Mar 27 2017
HEMEL HEMPSTEAD, England and VIENNA, Austria – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Ag... |
| 21.04.2015 | EUSA Pharma Appoints Lee Morley Chief Executive & Industry Veteran Goran Ando to Board of Directors | Apr 21 2015
HEMEL HEMPSTEAD, United Kingdom – – EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göra... |
| 24.03.2015 | EUSA Pharma Spins Out of Jazz Pharma With Backing from Essex Woodlands | Mar 24 2015
HEMEL HEMPSTEAD, United Kingdom—After completing a $700 million deal to sell EUSA Pharma Inc. to Jazz Pharmaceuticals PLC in 2012, Essex Woodlands has teamed up with EUSA’s founding Chief Executive Bryan Morton to spin the comp... |
| 23.03.2015 | EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business | Mar 23 2015
HEMEL HEMPSTEAD, United Kingdom –– EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced its official launch following the acquisition of five approved specialty... |
| 22.11.2011 | With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus | Nov 22 2011
Executive Summary
U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning ... |
| 18.11.2011 | Eusa Pharma gets green light for drug treatment of leukemia | Orphan drugs are classified as those treating niche patient populations of under 200,000. Eusa estimates that about 400-600 patients suffer allergic reactions from the treatment.
Promoted
This Patient Experience Checklist Is Your Key To Suc... |
| 05.01.2011 | EUSA Pharma Announces Priority Review Status for ERWINASE BLA | Jan 05 2011
LANGHORNE, Pennsylvania and OXFORD, United Kingdom – EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Appl... |
| 09.11.2010 | EUSA Pharma Submits ERWINASE® Biologics License Application (BLA) | Nov 09 2010
LANGHORNE, Pennsylvania and OXFORD, United Kingdom -– EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biolog... |
| 31.08.2010 | Essex Woodlands to Acquire Health Care Portfolio | Aug 31 2010
LONDON, United Kingdom—Essex Woodlands Health Ventures (“Essex Woodlands”) announced today that it has agreed to purchase a portfolio of investments in health care companies from Goldman Sachs. Financial terms of the transactio... |
| 11.03.2008 | Life-science briefing: Tuesday, March 11, 2008 | TODAY’S HEADLINES:
Affinergy gets $3M in grants for biological “linkers” (release)
Specialty pharma EUSA raises $50M, spends $23M for public biotech Cytogen (release)
Calderome takes in $12M for cancer diagnostics (peHUB)
Pulse Health raise... |
| 01.03.2007 | EUSA Pharma raises $175m for acquisitions and development led by 3i venture capital | EUSA Pharma Inc, a new transatlantic specialty pharmaceutical company focused on developing and marketing products for the hospital market both in Europe and theUnited States, announces the agreed acquisition of OPi SA (“OPi”), an integrate... |
| 01.03.2007 | EUSA Pharma raises USD 175 million for acquisition of OPi SA and further development of the Company | EUSA Pharma announces the agreed acquisition of OPi SA (“OPi”), an integrated biopharmaceutical company. The acquisition will create a strong platform on which to build a significant transatlantic business. The acquisition is being funded w... |
| - | SYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) as the Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) regardless ... | HEMEL HEMPSTEAD, England & BURLINGTON, Mass.--(BUSINESS WIRE)--Feb 25, 2021--
EUSA Pharma (UK) Limited (“ EUSA Pharma ”), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensiv... |
| - | Eusa Pharma gets green light for drug treatment of leukemia | Eusa Pharma, a British drug development company with its North American headquarters in Langhorne, Pennsylvania, has received approval from the U.S. Food and Drug Administration for its orphan drug Erwinaze for patients with acute lymphobla... |
